These differences might be attributed to the effector cell population (pre-stimulated PBMCs) investigated which still contains CD4+ T cells that can be engaged for tumor cell lysis via the scBsTaFv CD3-PSCA(MB1) but not via the scBsTaFv CD8-PSCA(MB1)). This evidence concerns the gene CD4 and neoplasm.